Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3)

Haijun Chen, Zhengduo Yang, Chunyong Ding, Ailian Xiong, Christopher Wild, Lili Wang, Na Ye, Guoshuai Cai, Rudolfo M. Flores, Ye Ding, Qiang Shen, Jia Zhou

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

In a continuing effort to develop orally bioavailable small-molecule STAT3 inhibitors as potential therapeutic agents for human cancer, a series of novel diversified analogues based on our identified lead compound HJC0149 (1) (5-chloro-N-(1,1-dioxo-1H-1λ6-benzo[b]thiophen-6-yl) -2-hydroxybenzamide, Eur. J. Med. Chem. 2013, 62, 498-507) have been rationally designed, synthesized, and pharmacologically evaluated. Molecular docking studies and biological characterization supported our earlier findings that the O-alkylamino-tethered side chain on the hydroxyl group is an effective and essential structural determinant for improving biological activities and druglike properties of these molecules. Compounds with such modifications exhibited potent antiproliferative effects against breast and pancreatic cancer cell lines with IC50 values from low micromolar to nanomolar range. Among them, the newly discovered STAT3 inhibitor 12 (HJC0416) displayed an intriguing anticancer profile both in vitro and in vivo (i.p. & p.o.). More importantly, HJC0416 is an orally bioavailable anticancer agent as a promising candidate for further development.

Original languageEnglish (US)
Pages (from-to)195-203
Number of pages9
JournalEuropean Journal of Medicinal Chemistry
Volume82
DOIs
StatePublished - Jul 23 2014

Fingerprint

STAT3 Transcription Factor
Antineoplastic Agents
Molecules
Lead compounds
Bioactivity
Pancreatic Neoplasms
Hydroxyl Radical
Inhibitory Concentration 50
Cells
Breast Neoplasms
Cell Line
(5-chloro-N-(1,1-dioxo-1H-1lamda(6)-benzo(b)thiophen-6-yl)-2-hydroxybenzamide
Neoplasms
Therapeutics

Keywords

  • Anticancer agents
  • Breast cancer
  • Oral bioavailability
  • Pancreatic cancer
  • STAT3 inhibitors

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Pharmacology
  • Medicine(all)

Cite this

Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3). / Chen, Haijun; Yang, Zhengduo; Ding, Chunyong; Xiong, Ailian; Wild, Christopher; Wang, Lili; Ye, Na; Cai, Guoshuai; Flores, Rudolfo M.; Ding, Ye; Shen, Qiang; Zhou, Jia.

In: European Journal of Medicinal Chemistry, Vol. 82, 23.07.2014, p. 195-203.

Research output: Contribution to journalArticle

Chen, Haijun ; Yang, Zhengduo ; Ding, Chunyong ; Xiong, Ailian ; Wild, Christopher ; Wang, Lili ; Ye, Na ; Cai, Guoshuai ; Flores, Rudolfo M. ; Ding, Ye ; Shen, Qiang ; Zhou, Jia. / Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3). In: European Journal of Medicinal Chemistry. 2014 ; Vol. 82. pp. 195-203.
@article{ec87df57497248fdbb77ea14716d23f7,
title = "Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3)",
abstract = "In a continuing effort to develop orally bioavailable small-molecule STAT3 inhibitors as potential therapeutic agents for human cancer, a series of novel diversified analogues based on our identified lead compound HJC0149 (1) (5-chloro-N-(1,1-dioxo-1H-1λ6-benzo[b]thiophen-6-yl) -2-hydroxybenzamide, Eur. J. Med. Chem. 2013, 62, 498-507) have been rationally designed, synthesized, and pharmacologically evaluated. Molecular docking studies and biological characterization supported our earlier findings that the O-alkylamino-tethered side chain on the hydroxyl group is an effective and essential structural determinant for improving biological activities and druglike properties of these molecules. Compounds with such modifications exhibited potent antiproliferative effects against breast and pancreatic cancer cell lines with IC50 values from low micromolar to nanomolar range. Among them, the newly discovered STAT3 inhibitor 12 (HJC0416) displayed an intriguing anticancer profile both in vitro and in vivo (i.p. & p.o.). More importantly, HJC0416 is an orally bioavailable anticancer agent as a promising candidate for further development.",
keywords = "Anticancer agents, Breast cancer, Oral bioavailability, Pancreatic cancer, STAT3 inhibitors",
author = "Haijun Chen and Zhengduo Yang and Chunyong Ding and Ailian Xiong and Christopher Wild and Lili Wang and Na Ye and Guoshuai Cai and Flores, {Rudolfo M.} and Ye Ding and Qiang Shen and Jia Zhou",
year = "2014",
month = "7",
day = "23",
doi = "10.1016/j.ejmech.2014.05.049",
language = "English (US)",
volume = "82",
pages = "195--203",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3)

AU - Chen, Haijun

AU - Yang, Zhengduo

AU - Ding, Chunyong

AU - Xiong, Ailian

AU - Wild, Christopher

AU - Wang, Lili

AU - Ye, Na

AU - Cai, Guoshuai

AU - Flores, Rudolfo M.

AU - Ding, Ye

AU - Shen, Qiang

AU - Zhou, Jia

PY - 2014/7/23

Y1 - 2014/7/23

N2 - In a continuing effort to develop orally bioavailable small-molecule STAT3 inhibitors as potential therapeutic agents for human cancer, a series of novel diversified analogues based on our identified lead compound HJC0149 (1) (5-chloro-N-(1,1-dioxo-1H-1λ6-benzo[b]thiophen-6-yl) -2-hydroxybenzamide, Eur. J. Med. Chem. 2013, 62, 498-507) have been rationally designed, synthesized, and pharmacologically evaluated. Molecular docking studies and biological characterization supported our earlier findings that the O-alkylamino-tethered side chain on the hydroxyl group is an effective and essential structural determinant for improving biological activities and druglike properties of these molecules. Compounds with such modifications exhibited potent antiproliferative effects against breast and pancreatic cancer cell lines with IC50 values from low micromolar to nanomolar range. Among them, the newly discovered STAT3 inhibitor 12 (HJC0416) displayed an intriguing anticancer profile both in vitro and in vivo (i.p. & p.o.). More importantly, HJC0416 is an orally bioavailable anticancer agent as a promising candidate for further development.

AB - In a continuing effort to develop orally bioavailable small-molecule STAT3 inhibitors as potential therapeutic agents for human cancer, a series of novel diversified analogues based on our identified lead compound HJC0149 (1) (5-chloro-N-(1,1-dioxo-1H-1λ6-benzo[b]thiophen-6-yl) -2-hydroxybenzamide, Eur. J. Med. Chem. 2013, 62, 498-507) have been rationally designed, synthesized, and pharmacologically evaluated. Molecular docking studies and biological characterization supported our earlier findings that the O-alkylamino-tethered side chain on the hydroxyl group is an effective and essential structural determinant for improving biological activities and druglike properties of these molecules. Compounds with such modifications exhibited potent antiproliferative effects against breast and pancreatic cancer cell lines with IC50 values from low micromolar to nanomolar range. Among them, the newly discovered STAT3 inhibitor 12 (HJC0416) displayed an intriguing anticancer profile both in vitro and in vivo (i.p. & p.o.). More importantly, HJC0416 is an orally bioavailable anticancer agent as a promising candidate for further development.

KW - Anticancer agents

KW - Breast cancer

KW - Oral bioavailability

KW - Pancreatic cancer

KW - STAT3 inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84902175603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902175603&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2014.05.049

DO - 10.1016/j.ejmech.2014.05.049

M3 - Article

VL - 82

SP - 195

EP - 203

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -